SG Americas Securities’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-14,035
Closed -$216K 3369
2025
Q4
$216K Sell
14,035
-8,207
-37% -$163K ﹤0.01% 2893
2025
Q3
$455K Sell
22,242
-14,131
-39% -$285K ﹤0.01% 2192
2025
Q2
$730K Buy
36,373
+23,261
+177% +$440K ﹤0.01% 1383
2025
Q1
$258K Sell
13,112
-3,517
-21% -$75.7K ﹤0.01% 2339
2024
Q4
$374K Buy
16,629
+6,616
+66% +$172K ﹤0.01% 1605
2024
Q3
$256K Buy
+10,013
New +$232K ﹤0.01% 2282
2024
Q2
Sell
-9,430
Closed -$166K 2970
2024
Q1
$166K Sell
9,430
-4,071
-30% -$62.5K ﹤0.01% 2116
2023
Q4
$187K Buy
13,501
+2,041
+18% +$25K ﹤0.01% 2225
2023
Q3
$157K Buy
+11,460
New +$193K ﹤0.01% 2465
2020
Q4
Sell
-1,642
Closed -$134K 3368
2020
Q3
$134K Buy
+1,642
New +$148K ﹤0.01% 2334

Other funds holding ELVN